FDA Inspection
Sciegen Pharmaceuticals IncSciegen Pharmaceuticals Inc – FDA Inspection, Apr 21, 2023
Record Details
This FDA Inspection record concerns Sciegen Pharmaceuticals Inc, with an inspection on April 21, 2023, issued by the Center for Drug Evaluation and Research, covering drugs.
View Company Profile
ID · 78debf30-0ef4-42cc-be44-6bb8ef0669d0
Inspection Facts
Official Action Indicated (OAI)
Significant objectionable conditions were found and regulatory or administrative action is recommended.
- Inspection number
- 1204858
- FDA center
- Human Drugs
- Project area
- Bioresearch Monitoring
- Outcome
- Form 483 issued
Other FDA inspections of Sciegen Pharmaceuticals Inc
13| Date | Classification | Office | Project area |
|---|---|---|---|
| May 15, 2026 | Not classified | New York District Office | Drug Quality Assurance |
| December 19, 2025 | NAI | Bioresearch Monitoring | |
| February 20, 2024 | NAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| September 2, 2022 | VAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| December 20, 2021 | VAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
Other documents for Sciegen Pharmaceuticals Inc
- FDA Inspection 1317246 - 2026-05-15
- FDA Inspection 1297968 - 2025-12-19
- FDA Inspection 1229682 - 2024-02-20
- FDA Inspection 1178870 - 2022-09-02
- FDA Inspection 1159297 - 2021-12-20
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.